Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
478 Leser
Artikel bewerten:
(2)

Tracelink, Inc.: TraceLink Named to the 2025 RXinsider Pharmacy500 List for Excellence in Pharmacy Supply Chain Innovation

TraceLink recognized for advancing digitalization and orchestration in the pharmacy supply chain, ensuring safe and timely access to medications

BOSTON, Jan. 22, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, is honored to be named to the Pharmacy500 list for the second year in a row, recognizing 500 organizations that have made a significant impact on the U.S. pharmacy industry over the past year.


"As regulations like the Drug Supply Chain Security Act (DSCSA) reshape the industry, our focus remains on empowering our customers with transformative solutions that ensure compliance, enhance safety, and drive operational excellence," said Shabbir Dahod, President and CEO of TraceLink. "This recognition reflects the trust that our growing digital network community places in TraceLink to help navigate the complexities of the modern supply chain while delivering impactful results to patients."

TraceLink specializes in a comprehensive suite of platform services that address key challenges in the pharmaceutical industry, including DSCSA compliance, track-and-trace orchestration, pharmacy and supply chain inventory visibility, and targeted product recall identification. Furthermore, with the recent launch of OPUS, the Orchestration Platform for Universal Solutions, democratized access to end-to-end supply chain integration and orchestration is finally available for customers and trading partners that wish to propel their supply chain management function to new heights of innovation and efficiency.

Gregory Cianfarani, RPh, Founder and CEO of RXinsider, established the Pharmacy500 to honor companies and organizations that are making a meaningful impact on the pharmaceutical industry. According to Cianfarani, the award "celebrates those companies that are transforming the pharmacy landscape - whether by driving operational efficiencies or advancing exceptional patient care."

In 2024, TraceLink welcomed more than 75 new pharmacy logos to its network, bringing the total number of pharmacy customers to more than 410. This growth reflects a strong demand for TraceLink's innovative solutions, which are helping pharmacies streamline operations and ensure compliance in an increasingly complex regulatory environment. This impressive expansion showcases the widespread adoption of TraceLink's solutions, as customers in the pharmaceutical supply chain industry continue to turn to the platform to enhance efficiency and navigate the evolving regulatory landscape.

With the Magnum release of the OPUS platform earlier this year, TraceLink set a new standard for compliance, supply chain integrity, and process optimization. This milestone innovation solidified TraceLink's position as a leader in the industry, earning its well-deserved recognition among the top organizations driving transformation in the pharmacy supply chain.

To learn more about TraceLink solutions, visit: https://www.tracelink.com/.

About Rxinsider:
Headquartered in West Warwick, Rhode Island, RXinsider is a pharmacist-founded marketing/communications (MARCOM) and market intelligence (INTEL) company focused on pharmacy operations and the companies supporting dispensing pharmacies. Through our publications, digital platforms, market research, and training resources, RXinsider educates pharmacy management and industry professionals on the products, services, and trends that impact pharmacy operations across the supply chain.

About TraceLink
TraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of healthcare products, ensuring that every patient gets the medicines they need when needed, safely and securely.

Logo - https://mma.prnewswire.com/media/1004729/TraceLink_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/tracelink-named-to-the-2025-rxinsider-pharmacy500-list-for-excellence-in-pharmacy-supply-chain-innovation-302356574.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.